Company Profile For Cephalon, Inc.

Cephalon, Inc. is an international biopharmaceutical company engaged in the discovery, development and commercialization of products in three therapeutic areas: central nervous system (CNS), pain and oncology. In addition to conducting an active research and development program, the Company markets seven products in the United States and numerous products in countries throughout Europe and the world. Its principal product is PROVIGIL (modafinil) Tablets [C-IV], consisted 51% of its total consolidated net sales, during the year ended December 31, 2008. PROVIGIL is indicated for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSA/HS) and shift work sleep disorder (SWSD). Its other principal products are FENTORA (fentanyl buccal tablet) [C-II] and ACTIQ (oral transmucosal fentanyl citrate) [C-II] (including its generic version of ACTIQ (generic OTFC)). In August 2009, the Company acquired Arana Therapeutics Limited.

BRIEF: For the nine months ended 30 September 2009, Cephalon,Inc.'s revenues increased 13% to $1.62B. Net income increased 31% to $246.1M. Revenues reflect an increase in the sales of NUVIGIL. Net income also reflects lower cost of sales, a decrease in selling, genral & administrative expense, an absence of settlement reserve and an increse in other income net. The company founded in 1987. It's is an international biopharmaceutical company.